Combining oral targeted therapies shows early anti-tumour activity for advanced melanoma from mek sarah Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Dr Infante talks to ecancertv at ASCO 2011, Chicago, about a new trial he has been working on at the Sarah Canon Research Institute: A Phase I trial showed that a combination of two oral targeted therapies – the oral MEK inhibitor GSK212 and the oral BRAF inhibitor GSK436 – was safe and had preliminary anti-tumour activity in patients with advanced melanoma. The trial results are potentially important because they show promising synergistic anti-cancer activity for two oral targeted therapie
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)